Literature DB >> 32135029

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.

M Lia Palomba1,2, Joachim Yahalom3, Brandon S Imber3, Michel Sadelain4, Carl DeSelm5, Connie Batlevi1,2, Renier J Brentjens2, Parastoo B Dahi6, Sergio Giralt6, Jae H Park2, Craig Sauter6, Michael Scordo6, Gunjan Shah6, Miguel-Angel Perales6.   

Abstract

Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  CAR T cells; chimeric antigen receptor T cells; diffuse large B cell lymphoma; radiotherapy; relapsed/refractory; salvage therapy

Mesh：

Substances：

Year:  2020        PMID： 32135029      PMCID： PMC7329607          DOI： 10.1111/bjh.16541

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  26 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.

Authors:  Craig S Sauter; Brigitte Senechal; Isabelle Rivière; Ai Ni; Yvette Bernal; Xiuyan Wang; Terence Purdon; Malloury Hall; Ashvin N Singh; Victoria Z Szenes; Sarah Yoo; Ahmet Dogan; Yongzeng Wang; Craig H Moskowitz; Sergio Giralt; Matthew J Matasar; Miguel-Angel Perales; Kevin J Curran; Jae Park; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2019-07-01       Impact factor: 22.113

Review 3.  The promise of CAR T-cell therapy in aggressive B-cell lymphoma.

Authors:  Ranjit Nair; Sattva S Neelapu
Journal:  Best Pract Res Clin Haematol       Date:  2018-08-01       Impact factor: 3.020

4.  Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.

Authors:  Gary A Ulaner; Debra A Goldman; Craig S Sauter; Jocelyn Migliacci; Joshua Lilienstein; Mithat Gönen; Heiko Schöder; Craig H Moskowitz; Andrew D Zelenetz
Journal:  Radiology       Date:  2015-06-02       Impact factor: 11.105

Review 5.  Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.

Authors:  Arnab Ghosh; Ioannis Politikos; Miguel-Angel Perales
Journal:  Curr Opin Oncol       Date:  2017-11       Impact factor: 3.645

6.  Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

Authors:  Carl DeSelm; M Lia Palomba; Joachim Yahalom; Mohamad Hamieh; Justin Eyquem; Vinagolu K Rajasekhar; Michel Sadelain
Journal:  Mol Ther       Date:  2018-09-13       Impact factor: 11.454

7.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 8.  Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART).

Authors:  James P Flynn; Mark H O'Hara; Saumil J Gandhi
Journal:  Transl Lung Cancer Res       Date:  2017-04

9.  Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Authors:  Victor A Chow; Ajay K Gopal; David G Maloney; Cameron J Turtle; Stephen D Smith; Chaitra S Ujjani; Mazyar Shadman; Ryan D Cassaday; Brian G Till; Yolanda D Tseng; Edus H Warren; Andrei R Shustov; Manoj P Menon; Sandra Bhark; Utkarsh H Acharya; Erin Mullane; Lindsay M Hannan; Jenna M Voutsinas; Ted A Gooley; Ryan C Lynch
Journal:  Am J Hematol       Date:  2019-05-21       Impact factor: 10.047

10.  Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.

Authors:  Bradford S Hoppe; Craig H Moskowitz; Daniel A Filippa; Chaya S Moskowitz; Tarun Kewalramani; Andrew D Zelenetz; Andrew D Zelenet; Joachim Yahalom
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544
View more
  10 in total

Review 1.  Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas.

Authors:  Anagha Deshpande; William Rule; Allison Rosenthal
Journal:  Curr Treat Options Oncol       Date:  2022-02-15

Review 2.  Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Authors:  Miguel-Angel Perales; Larry D Anderson; Tania Jain; Saad S Kenderian; Olalekan O Oluwole; Gunjan L Shah; Jakub Svoboda; Mehdi Hamadani
Journal:  Transplant Cell Ther       Date:  2022-06-26

Review 3.  Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.

Authors:  Haneen Shalabi; Juliane Gust; Agne Taraseviciute; Pamela L Wolters; Allison B Leahy; Carlos Sandi; Theodore W Laetsch; Lori Wiener; Rebecca A Gardner; Veronique Nussenblatt; Joshua A Hill; Kevin J Curran; Timothy S Olson; Colleen Annesley; Hao-Wei Wang; Javed Khan; Marcelo C Pasquini; Christine N Duncan; Stephan A Grupp; Michael A Pulsipher; Nirali N Shah
Journal:  Nat Rev Clin Oncol       Date:  2021-01-25       Impact factor: 66.675

Review 4.  Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia.

Authors:  Muna Qayed; Marie Bleakley; Nirali N Shah
Journal:  Curr Opin Hematol       Date:  2021-11-01       Impact factor: 3.218

Review 5.  Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review.

Authors:  Franziska Hauth; Alice Y Ho; Soldano Ferrone; Dan G Duda
Journal:  JAMA Oncol       Date:  2021-07-01       Impact factor: 33.006

Review 6.  Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy.

Authors:  Penny Q Fang; Jillian R Gunther; Susan Y Wu; Bouthaina S Dabaja; Loretta J Nastoupil; Sairah Ahmed; Sattva S Neelapu; Chelsea C Pinnix
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

Review 7.  Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions.

Authors:  Julio C Chavez; Farah Yassine; Jose Sandoval-Sus; Mohamed A Kharfan-Dabaja
Journal:  Int J Hematol Oncol       Date:  2021-08-03

8.  Case Report: Subtotal Lymphoid and Total Marrow Irradiation as Bridge Therapy to CD19-Directed CAR T Cells in a Chemorefractory DLBCL With Leukemic Involvement.

Authors:  Simonetta Saldi; Vincenzo Maria Perriello; Lorenza Falini; Loredana Ruggeri; Christian Fulcheri; Sara Ciardelli; Alessandra Innocente; Stelvio Ballanti; Nicodemo Baffa; Leonardo Flenghi; Antonio Pierini; Cynthia Aristei; Brunangelo Falini
Journal:  Front Immunol       Date:  2022-07-14       Impact factor: 8.786

Review 9.  Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy.

Authors:  Laetitia Vercellino; Dorine de Jong; Roberta di Blasi; Salim Kanoun; Ran Reshef; Lawrence H Schwartz; Laurent Dercle
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

Review 10.  Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview.

Authors:  Cristina Ferrari; Nicola Maggialetti; Tamara Masi; Anna Giulia Nappi; Giulia Santo; Artor Niccoli Asabella; Giuseppe Rubini
Journal:  J Pers Med       Date:  2021-03-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.